Skip to main content Skip to navigation
Hamburger Menu
Search icon
Order lookup icon Order lookup icon
Order Lookup
Country Selector Country Selector
United States (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      Purified NA/LE Mouse Anti-Human TIGIT
      Purified NA/LE Mouse Anti-Human TIGIT
      Flow cytometric analysis of Recombinant Human TIGIT Human IgG1 Fc Chimera Protein (TIGIT-Fc) binding blockade by Purified NA/LE Mouse Anti-Human TIGIT antibody on HeLa Cells. Cells from the human HeLa (Cervical adenocarcinoma, ATCC CCL-2) cell line were preincubated with either Recombinant Human IgG1 Fc Protein (Human IgG1 Fc; R&D Systems, Cat. No. 110-HG; 0.5 µg/test; Histogram 4) or Recombinant Human TIGIT Human IgG1 Fc Chimera Protein (TIGIT-Fc; R&D Systems Cat. No. 7898-TGB-100; 0.5 µg/test; Histogram 3). The binding of Recombinant Human TIGIT-Fc was blocked with Purified NA/LE Mouse Anti-Human TIGIT antibody (TgMab-2 Antibody; Cat. No. 568674; 20 µg/test; Histogram 2), but not blocked by Purified Mouse IgG1 κ Isotype Control (Isotype Control; Cat. No. 556648; 20 µg/test; Histogram 1). The degree of Human TIGIT-Fc  binding was measured by fluorescent staining with Biotinylated Goat Anti-Human IgG (H+L) Antibody (Vector Lab, Cat. No. BA-3000-1.5) followed by PE Streptavidin (Cat. No. 554061). The histograms were derived from gated events with the forward and side light-scatter characteristics of viable cells. Flow cytometric analysis was performed using a BD LSRFortessa™ Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
      Purified NA/LE Mouse Anti-Human TIGIT
      Flow cytometric analysis of Recombinant Human TIGIT Human IgG1 Fc Chimera Protein (TIGIT-Fc) binding blockade by Purified NA/LE Mouse Anti-Human TIGIT antibody on HeLa Cells. Cells from the human HeLa (Cervical adenocarcinoma, ATCC CCL-2) cell line were preincubated with either Recombinant Human IgG1 Fc Protein (Human IgG1 Fc; R&D Systems, Cat. No. 110-HG; 0.5 µg/test; Histogram 4) or Recombinant Human TIGIT Human IgG1 Fc Chimera Protein (TIGIT-Fc; R&D Systems Cat. No. 7898-TGB-100; 0.5 µg/test; Histogram 3). The binding of Recombinant Human TIGIT-Fc was blocked with Purified NA/LE Mouse Anti-Human TIGIT antibody (TgMab-2 Antibody; Cat. No. 568674; 20 µg/test; Histogram 2), but not blocked by Purified Mouse IgG1 κ Isotype Control (Isotype Control; Cat. No. 556648; 20 µg/test; Histogram 1). The degree of Human TIGIT-Fc  binding was measured by fluorescent staining with Biotinylated Goat Anti-Human IgG (H+L) Antibody (Vector Lab, Cat. No. BA-3000-1.5) followed by PE Streptavidin (Cat. No. 554061). The histograms were derived from gated events with the forward and side light-scatter characteristics of viable cells. Flow cytometric analysis was performed using a BD LSRFortessa™ Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
      Product Details
      Down Arrow Up Arrow


      BD Pharmingen™
      T-cell immunoreceptor with Ig and ITIM domains; VSIG9; VSTM3; WUCAM
      Human (QC Testing)
      Mouse BALB/c IgG1, κ
      Human TIGIT Transfected Cell Line
      Blocking, Flow cytometry (Tested During Development)
      1.0 mg/ml
      201633
      No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.
      RUO


      Preparation And Storage

      Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. This preparation contains no preservatives, thus it should be handled under aseptic conditions.
      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      2. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      3. An isotype control should be used at the same concentration as the antibody of interest.
      4. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      Show More blue down arrow Show Less blue up arrow
      568674 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      TgMab-2

      The TgMab-2 monoclonal antibody specifically recognizes TIGIT (T cell Immunoreceptor with Ig and ITIM domains) which is also known as Vstm3 (V-set and transmembrane domain-containing 3), Vsig9 (V-set and Ig domain-containing 9) and WUCAM (Washington University Cell Adhesion Molecule). TIGIT is a 30-34 kDa single pass type I transmembrane glycoprotein that belongs to the CD28 family within the Ig superfamily. TIGIT has an extracellular region with a V-type Ig-like domain, transmembrane sequence, and a cytoplasmic domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on NK cells and subsets of activated and memory T cells, regulatory T cells (Treg), and T follicular helper (Tfh) cells. TIGIT binds to CD112 (PVRL2/Nectin-2) and CD155 (PVR/Necl-5) that are expressed on dendritic cells (DC), endothelial cells, fibroblasts, and some tumor cells and can induce IL-10 release and inhibition of IL-12 production. Ligand-bound TIGIT downregulates TCR-mediated T cell activation and proliferation and can block NK cell-mediated cytotoxicity.

      568674 Rev. 1
      Format Details
      Down Arrow Up Arrow
      NA/LE
      NA/LE refers to the culture and purification methods and buffer used to produce purified antibodies with no azide and low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.NA/LE are perfectly suited to be used in culture or in vivo (for nonhuman studies) for functional assays — blocking, neutralizing, activation or depletion — where the presence of azide may damage cells or exogenous endotoxin may signal or activate cells.
      NA/LE
      568674 Rev.1
      Citations & References
      Down Arrow Up Arrow
      View product citations for antibody "568674" on CiteAb

      Development References (3)

      1. Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.. J Immunother Cancer. 2022; 10(4):e004711. (Biology). View Reference
      2. Shibuya A, Shibuya K. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.. Int Immunol. 2021; 33(12):687-692. (Biology). View Reference
      3. Yu X, Harden K, Gonzalez LC, Francesco M, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009; 10(1):48-57. (Biology). View Reference
      568674 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.